Levofloxacin Global Market Report 2024

The levofloxacin market has grown strongly in recent years. It will grow from $1.67 billion in 2023 to $1.77 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The expansion observed in the historical period can be attributed to factors such as the demand for antibiotics, an increase in respiratory tract infections, a rise in skin and soft tissue infections, and the emergence of multidrug-resistant strains of bacteria.

The levofloxacin market is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The anticipated growth in the forecast period can be attributed to dynamics in the aging population, an increased incidence of respiratory infections, a rise in cases of urinary tract infections, the global challenge of antibiotic resistance, and an expansion in surgical procedures. Key trends expected in the forecast period include the adoption of levofloxacin in the treatment of urinary tract infections (UTIs), exploration of combination therapies, continuous monitoring for safety profiles, a shift towards outpatient prescriptions, and a global focus on health preparedness for infectious diseases.

The anticipated increase in the number of bacterial infections is set to drive the growth of the levofloxacin market in the future. Bacterial infections, resulting from the invasion of the body by single-celled microscopic organisms known as bacteria, can be effectively alleviated by levofloxacin. This antibiotic inhibits DNA topoisomerases, thereby hindering DNA synthesis, and is utilized in treating conditions such as strep throat, tuberculosis (TB), whooping cough (pertussis), and related symptoms. For example, the Global Tuberculosis Report 2022 published by the World Health Organization in October 2022 estimated a global incidence of 10.6 million TB cases, with a rate of 134 cases per 100,000 population in 2021. Consequently, the increasing prevalence of bacterial infections is a driving force behind the growth of the levofloxacin market.

The growing aging population is expected to contribute significantly to the expansion of the levofloxacin market. An aging population refers to an increasing proportion of individuals aged 60 years and above in a given population. Respiratory infections, particularly pneumonia, are prevalent among the elderly, often requiring prompt and effective antibiotic treatment. For instance, as of September 2023, the World Economic Forum reported that more than 1 in 10 people in Japan are aged 80 or older. This demographic shift towards an aging population is a key factor driving the growth of the levofloxacin market.

A prominent trend in the levofloxacin market is the emergence of advanced and targeted therapies. Major companies in the market are dedicated to innovating new products to enhance efficacy and maintain their market position. For example, in February 2022, Santen Pharmaceutical, a Japan-based pharmaceutical and medical device company, introduced Ducressa - an innovative fixed-dose combination (FDC) of levofloxacin and dexamethasone eye drops. Designed for the prevention and treatment of inflammation and infection associated with cataract surgery in adults, Ducressa represents a breakthrough prophylactic treatment by combining the broad-spectrum antibiotic efficacy of levofloxacin with the anti-inflammatory properties of dexamethasone.

Major companies in the levofloxacin market are engaging in strategic collaborations with prominent manufacturing partners. These strategic partnerships involve cooperative efforts between organizations to achieve specific business objectives. For example, in June 2023, CEOLIA Pharma Company Ltd., a Japan-based specialty pharmaceutical company, launched Comlex Otic Solution 1.5% (levofloxacin hydrate), an antibacterial OTIC solution developed in collaboration with NanoCarrier Co., Ltd., a Japan-based pharmaceutical company specializing in research and development. This novel medication, an antibacterial OTIC solution for treating otitis externa and otitis media, represents an innovative approach in the ears, noses, and throats (ENT) field.

In July 2022, Innoviva Inc., a US-based biopharmaceutical company, completed the acquisition of Entasis Therapeutics Holdings Inc. for $42.4 million. This strategic move aims to enhance Innoviva's portfolio with potentially first-in-class medications for treating multidrug-resistant gram-negative bacteria, including the main asset SUL-DUR. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company operating in the levofloxacin market, brings expertise in antibacterial and antibiotic medicines to complement Innoviva's strategic objectives.

Major companies operating in the levofloxacin market report are Zydus Lifesciences Limited, Dr. Reddy's Laboratories Limited, Lupin Limited, Pax Healthcare, Aden Healthcare, Allenge India Pharmaceuticals Private Limited, Alna Biotech Private Limited, Bestochem Formulations Limited, Divine Savior Healthcare Private Limited, Glenmark Pharmaceuticals Limited, Cipla Limited, Alkem Laboratories Ltd., Sanofi S.A., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Unichem Laboratories, Macleods Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, Jubilant Pharmova Limited , Wockhardt, Hetero Drugs, Sandoz Group AG, Mankind Pharma, Intas Pharmaceuticals Ltd., Strides Pharma Science Ltd., Divis Laboratories Ltd., Ajanta Pharma Ltd., Panacea Biotec Limited.

North America was the largest region in the global levofloxacin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the levofloxacin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the levofloxacin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of levofloxacin are 250 mg tablets, 500 mg tablets, and 750 mg tablets. The 250 mg tablets contain levofloxacin at a dosage strength of 250 mg and are employed for the treatment of bacterial infections in the body. These tablets are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Levofloxacin is commonly used to address infections such as pneumonia, skin infections, kidney infections, bladder infections, among others.

The levofloxacin research report provides levofloxacin market statistics, including the levofloxacin industry's global market size, regional shares, competitors with a levofloxacin market share, detailed levofloxacin market segments, market trends and opportunities, and any further data you may need to thrive in the levofloxacin industry. This levofloxacin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The levofloxacin market consists of sales of levofloxacin-citric acid, levofloxacin hydrochloride, and levofloxacin-d3 sodium salt. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.